Alendronic acid

Generic Name: Alendronic acid

Brand Names: Adrovance, Binosto, Fosamax, Fosamax Plus D, Fosavance

Drug Type: Small Molecule

Chemical Formula: C_₄H_₁₃NO_₇P_₂

CAS Number: 66376-36-1

Unique Ingredient Identifier: X1J18R4W8P

Background: Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease. It functions by preventing resorption of bone.

Indication: Alendronic acid is indicated for the treatment and prevention of osteoporosis in men and postmenopausal women, treatment of glucocorticoid-induced osteoporosis, and Paget's disease of bone. However, alendronic acid is not indicated for use in pediatric populations or patients with a creatinine clearance <35mL/min.

Associated Conditions: Osteogenesis Imperfecta (OI), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget’s Disease

Clinical Trials

Romosozumab Effects on Bone Density, Muscle Mass, and Spine Surgery Outcomes

Phase 2

Not yet recruiting

Conditions: Osteoporosis, Post-menopausal

Interventions: Drug: Romosozumab
Drug: Alendronate (Fosamax)
Drug: Placebo Alendronate
Drug: Placebo Romosozumab

First Posted Date: 2025-05-15

Last Posted Date: 2025-05-15

Lead Sponsor: Nitin Agarwal

Target Recruit Count: 36

Registration Number: NCT06973109

Locations: 🇺🇸
University of Pittsburgh Medical Center (UPMC) - Presbyterian Hospital, Pittsburgh, Pennsylvania, United States

A Clinical Study on the Effect of Discontinuing Alendronate in Postmenopausal Women with Osteoporosis After a Treatment Period Without Fractures

Phase 4

Recruiting

Conditions: Osteoporosis in Post-menopausal Women

Interventions: Drug: Alendronate 70mg weekly

First Posted Date: 2025-03-07

Last Posted Date: 2025-03-07

Lead Sponsor: Odense University Hospital

Target Recruit Count: 1400

Registration Number: NCT06864130

Locations: 🇩🇰
Aalborg University Hospital, Aalborg, Denmark
🇩🇰
Bispebjerg Hospital, Copenhagen, Denmark
🇩🇰
Esbjerg Og Grindsted Sygehus, Esbjerg, Denmark

and more 4 locations

A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Alendronate in Healthy Adult Participants (MK-0616-027)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Alendronate
Drug: Enlicitide Decanoate

First Posted Date: 2025-01-14

Last Posted Date: 2025-02-18

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 36

Registration Number: NCT06772792

Locations: 🇺🇸
Celerion (Site 0001), Lincoln, Nebraska, United States

Precision Medicine Approach for Osteoporosis - Follow Up Study

Phase 4

Conditions: Osteoporosis

Interventions: Drug: Alendronate
Drug: Teriparatide

First Posted Date: 2024-02-20

Last Posted Date: 2025-04-08

Lead Sponsor: Paul F Netzel

Target Recruit Count: 40

Registration Number: NCT06264609

Locations: 🇺🇸
University of Kentucky, Lexington, Kentucky, United States

Alendronate for Osteonecrosis in Adults With Sickle Cell Disease

Phase 2

Recruiting

Conditions: Sickle Cell Disease
Sickle Cell Anemia
Osteonecrosis
Avascular Necrosis
Ischemic Necrosis

Interventions: Drug: Alendronate Sodium

First Posted Date: 2023-08-30

Last Posted Date: 2024-11-12

Lead Sponsor: University of California, Davis

Target Recruit Count: 24

Registration Number: NCT06016634

Locations: 🇺🇸
UC Davis Comprehensive Cancer Center, Sacramento, California, United States

Denosumab vs Alendronate After Vertebroplasty

Not Applicable

Recruiting

Conditions: Denosumab Allergy

Interventions: Drug: Alendronate
Drug: Denosumab
Drug: Placebo

First Posted Date: 2022-12-22

Last Posted Date: 2023-02-21

Lead Sponsor: Shenzhen People's Hospital

Target Recruit Count: 90

Registration Number: NCT05662358

Locations: 🇨🇳
Shenzhen People's Hospital, Shenzhen, Guangdong, China

Efficacy and Safety of Minodronate in Patients With Low Back Pain

Phase 4

Not yet recruiting

Conditions: Postmenopausal Osteoporosis

Interventions: Drug: Minodronate
Drug: Alendronate

First Posted Date: 2022-12-09

Last Posted Date: 2022-12-09

Lead Sponsor: Peking University Third Hospital

Target Recruit Count: 72

Registration Number: NCT05645289

Locations: 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China

A Single-blind RCT to Investigate the Effect of Alendronate on Knee Function Following ACLR

Phase 4

Recruiting

Conditions: ACL Reconstruction

Interventions: Drug: Alendronate (ALN)

First Posted Date: 2022-09-02

Last Posted Date: 2024-02-15

Lead Sponsor: Chinese University of Hong Kong

Target Recruit Count: 64

Registration Number: NCT05527548

Locations: 🇭🇰
Prince of Wales Hospital, Sha Tin, Hong Kong

Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease

Phase 4

Recruiting

Conditions: Osteoporosis, Postmenopausal
Nonalcoholic Fatty Liver

Interventions: Drug: Alendronate Sodium
Drug: Denosumab

First Posted Date: 2022-08-09

Last Posted Date: 2024-12-16

Lead Sponsor: Aristotle University Of Thessaloniki

Target Recruit Count: 70

Registration Number: NCT05493761

Locations: 🇬🇷
1st Department of Obstetrics and Gynecology, School, of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
🇬🇷
Department of Endocrinology, "Hippokration" General Hospital of Thessaloniki, Thessaloníki, Greece
🇬🇷
424 General Military Hospital, Thessaloníki, Greece

Efficacy and Safety of JMT103 in the Treatment of Glucocorticoid Induced Osteoporosis

Phase 2

Conditions: Glucocorticoid Induced Osteoporosis

Interventions: Drug: JMT103
Drug: Alendronate sodium
Drug: Alendronate sodium placebo
Drug: JMT103 placebo

First Posted Date: 2022-05-31

Last Posted Date: 2022-05-31

Lead Sponsor: Shanghai JMT-Bio Inc.

Target Recruit Count: 231

Registration Number: NCT05397938

Locations: 🇨🇳
Peking University First Hospital, Beijing, Beijing, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy